Sign In
to Vote &
Create Storyboards.
 
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, and XenoTech, a preclinical CRO and pioneer in collaborative research surrounding in vitro drug metabolism and pharmacokinetics (DMPK) services, has announced that an article describing a study to determine the potential of rose bengal disodium to cause drug-drug interactions has been published by Xenobiotica, a peer-reviewed scientific journal that publishes comprehensive research papers ...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard